CN110214141B - 作为ENaC抑制剂的苯并二唑鎓化合物 - Google Patents

作为ENaC抑制剂的苯并二唑鎓化合物 Download PDF

Info

Publication number
CN110214141B
CN110214141B CN201780084165.3A CN201780084165A CN110214141B CN 110214141 B CN110214141 B CN 110214141B CN 201780084165 A CN201780084165 A CN 201780084165A CN 110214141 B CN110214141 B CN 110214141B
Authority
CN
China
Prior art keywords
amino
methyl
pyrrolo
pyrazin
carboxamido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780084165.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN110214141A (zh
Inventor
C·麦卡锡
J·D·哈格雷夫
D·A·哈伊
T·B·斯科菲尔德
N·温特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enterprise Therapeutics Ltd
Original Assignee
Enterprise Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterprise Therapeutics Ltd filed Critical Enterprise Therapeutics Ltd
Publication of CN110214141A publication Critical patent/CN110214141A/zh
Application granted granted Critical
Publication of CN110214141B publication Critical patent/CN110214141B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780084165.3A 2016-11-22 2017-11-22 作为ENaC抑制剂的苯并二唑鎓化合物 Active CN110214141B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1619694.1A GB201619694D0 (en) 2016-11-22 2016-11-22 Compounds
GB1619694.1 2016-11-22
PCT/GB2017/053499 WO2018096325A1 (en) 2016-11-22 2017-11-22 Benzodiazolium compounds as enac inhibitors

Publications (2)

Publication Number Publication Date
CN110214141A CN110214141A (zh) 2019-09-06
CN110214141B true CN110214141B (zh) 2022-05-31

Family

ID=57993838

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780084165.3A Active CN110214141B (zh) 2016-11-22 2017-11-22 作为ENaC抑制剂的苯并二唑鎓化合物

Country Status (20)

Country Link
US (4) US10941149B2 (https=)
EP (1) EP3544981B1 (https=)
JP (1) JP6980014B2 (https=)
KR (1) KR102517273B1 (https=)
CN (1) CN110214141B (https=)
AU (1) AU2017364308B2 (https=)
CA (1) CA3043132A1 (https=)
DK (1) DK3544981T3 (https=)
EA (1) EA039607B1 (https=)
ES (1) ES2890226T3 (https=)
GB (1) GB201619694D0 (https=)
HU (1) HUE055692T2 (https=)
IL (1) IL266745B (https=)
MA (1) MA46878A (https=)
MX (1) MX389496B (https=)
PL (1) PL3544981T3 (https=)
PT (1) PT3544981T (https=)
TW (1) TWI756305B (https=)
WO (1) WO2018096325A1 (https=)
ZA (1) ZA201902710B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
GB201717051D0 (en) * 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds
GB201801355D0 (en) 2018-01-26 2018-03-14 Enterprise Therapeutics Ltd Compounds
GB201808093D0 (en) * 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds
GB201908453D0 (en) 2019-06-12 2019-07-24 Enterprise Therapeutics Ltd Compounds for treating respiratory disease
CR20220006A (es) 2019-06-12 2022-06-06 Tmem16A Ltd Compuestos para tratar enfermedad respiratoria
GB201910608D0 (en) 2019-07-24 2019-09-04 Enterprise Therapeutics Ltd Compounds
EP4259607A1 (en) * 2020-12-11 2023-10-18 Tmem16A Limited Benzimidazole derivatives for treating respiratory disease
CN118852442A (zh) 2023-04-26 2024-10-29 上海麦科思生物医药有限公司 抗ptk7抗体及其用途
GB202406247D0 (en) 2024-05-03 2024-06-19 Enterprise Therapeutics Ltd Compounds and pharmaceutical compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101142194A (zh) * 2005-03-14 2008-03-12 特兰斯泰克制药公司 吲哚衍生物，组合物及用作β-分泌酶抑制剂的方法
WO2016113167A1 (en) * 2015-01-12 2016-07-21 Boehringer Ingelheim International Gmbh Substituted benzimidazolium compounds useful in the treatment of respiratory diseases

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US6858614B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
US20050090505A1 (en) 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
AU2004266704B2 (en) 2003-08-18 2012-02-23 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
US7375107B2 (en) 2003-08-18 2008-05-20 Parion Sciences, Inc. Alaphatic pyrazinoylguanidine sodium channel blockers
JP2007502829A (ja) 2003-08-18 2007-02-15 パリオン・サイエンシィズ・インコーポレーテッド 環状ピラジノイルグアニジンナトリウムチャネルブロッカー
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
AU2004285053B2 (en) 2003-10-28 2010-10-21 Vertex Pharmaceuticals, Incorporated Benzimidazoles useful as modulators of ion channels
US7399766B2 (en) 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
US7807834B2 (en) 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526240D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
US8288391B2 (en) 2007-04-03 2012-10-16 Parion Sciences, Inc. Pyrazinoylguanidine compounds for use as taste modulators
CN101687851B (zh) 2007-05-07 2013-02-27 诺瓦提斯公司 有机化合物
WO2009019506A1 (en) 2007-08-03 2009-02-12 Astrazeneca Ab Heterocyclyc sulfonamides having edg-1 antagonistic activity
CL2008003651A1 (es) 2007-12-10 2009-06-19 Novartis Ag Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias.
WO2009139948A1 (en) 2008-02-26 2009-11-19 Johnson Michael R Poly aromatic sodium channel blockers
AU2009248179A1 (en) 2008-05-13 2009-11-19 Novartis Ag 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of arway diseases
CA2727196A1 (en) 2008-06-10 2009-12-17 Novartis Ag Organic compounds
WO2011028740A1 (en) 2009-09-03 2011-03-10 Glaxo Group Limited ENaC BLOCKERS
WO2011079087A1 (en) 2009-12-23 2011-06-30 Glaxo Group Limited Enac blockers
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
TW201204353A (en) * 2010-06-08 2012-02-01 Vertex Pharma Formulations of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
WO2013064450A1 (en) 2011-11-02 2013-05-10 Boehringer Ingelheim International Gmbh Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
US8859559B2 (en) 2011-12-20 2014-10-14 Boehringer Ingelheim International Gmbh Substituted pyrazines and their use in the treatment of disease
MX2014014648A (es) 2012-05-29 2015-09-04 Parion Sciences Inc Aminoamidas tipo dendrimero que poseen actividad bloqueadora del canal de sodio para el tratamiento de ojo reseco y otras enfermedades mucosas.
WO2014044849A1 (en) 2012-09-24 2014-03-27 Boehringer Ingelheim International Gmbh Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
SG10201708931XA (en) 2012-12-17 2017-12-28 Parion Sciences Inc Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
RU2018138195A (ru) 2012-12-17 2018-12-18 Пэрион Сайенсиз, Инк. Соединения 3,5-диамино-6-хлор-n-(n-(4- фенилбутил)карбамимидоил)пиразин-2-карбоксамида
ES2674665T3 (es) 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
WO2014177469A1 (en) 2013-04-30 2014-11-06 Boehringer Ingelheim International Gmbh,M Diaminopyrazine compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
US9656972B2 (en) 2013-07-02 2017-05-23 The California Institute For Biomedical Research Compounds for treatment of cystic fibrosis
JP6449870B2 (ja) 2013-07-08 2019-01-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肺および気道の疾患を処置するための上皮性ナトリウムチャネルの阻害剤としてのアミロライド型化合物
EP3022196B1 (en) 2013-07-15 2017-09-06 Boehringer Ingelheim International GmbH Novel benzimidazolium compounds
EP3022197B1 (en) 2013-07-15 2017-09-06 Boehringer Ingelheim International GmbH Novel tetra- and pentasubstituted benzimidazolium compounds
EP3022198B1 (en) 2013-07-15 2019-09-11 Boehringer Ingelheim International GmbH Novel 5-substituted benzimidazolium compounds
JP6449880B2 (ja) 2013-08-08 2019-01-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ピラジンアミド化合物
JP6667538B2 (ja) 2015-01-12 2020-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系疾患の治療に有用な置換ベンズイミダゾリウム化合物
EP3245202B1 (en) 2015-01-12 2020-03-11 Boehringer Ingelheim International GmbH Tetrasubstituted benzimidazolium compounds useful in the treatment of respiratory diseases
US9981954B2 (en) 2015-01-12 2018-05-29 Boehringer Ingelheim International Gmbh 2-(pyrazin-2-ylcarbonylaminomethyl) benzimidazolium compounds as epithelial sodium channel inhibitors
CA2996087A1 (en) 2015-08-20 2017-02-23 Boehringer Ingelheim International Gmbh Annelated phenoxyacetamides
BR112018002115A2 (pt) 2015-08-20 2018-09-18 Boehringer Ingelheim Int benzamidas aneladas
GB201610854D0 (en) * 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) * 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101142194A (zh) * 2005-03-14 2008-03-12 特兰斯泰克制药公司 吲哚衍生物，组合物及用作β-分泌酶抑制剂的方法
WO2016113167A1 (en) * 2015-01-12 2016-07-21 Boehringer Ingelheim International Gmbh Substituted benzimidazolium compounds useful in the treatment of respiratory diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Novel small molecule epithelial sodium channel inhibitors as potential therapeutics in cystic fibrosis - a patent evaluation;SCHOENBERGER，等;《EXPERT OPIN. THER. PATENTS》;20131231;第23卷(第10期);第1383-1389页 *

Also Published As

Publication number Publication date
MA46878A (fr) 2019-10-02
NZ753048A (en) 2024-09-27
HUE055692T2 (hu) 2021-12-28
BR112019009864A2 (pt) 2019-08-27
IL266745A (en) 2019-07-31
MX389496B (es) 2025-03-20
TW201833111A (zh) 2018-09-16
PT3544981T (pt) 2021-09-23
AU2017364308B2 (en) 2021-03-11
ES2890226T3 (es) 2022-01-18
KR102517273B1 (ko) 2023-04-03
EA201991253A1 (ru) 2019-11-29
US20210147432A1 (en) 2021-05-20
US20250304590A1 (en) 2025-10-02
US10941149B2 (en) 2021-03-09
KR20190084076A (ko) 2019-07-15
IL266745B (en) 2021-12-01
TWI756305B (zh) 2022-03-01
US20190315757A1 (en) 2019-10-17
US12371436B2 (en) 2025-07-29
MX2019005934A (es) 2019-11-12
JP6980014B2 (ja) 2021-12-15
EP3544981A1 (en) 2019-10-02
US20240067653A1 (en) 2024-02-29
EA039607B1 (ru) 2022-02-16
DK3544981T3 (da) 2021-09-20
WO2018096325A1 (en) 2018-05-31
PL3544981T3 (pl) 2021-12-20
AU2017364308A1 (en) 2019-05-23
JP2019535747A (ja) 2019-12-12
EP3544981B1 (en) 2021-06-23
CN110214141A (zh) 2019-09-06
US11739094B2 (en) 2023-08-29
GB201619694D0 (en) 2017-01-04
ZA201902710B (en) 2021-10-27
CA3043132A1 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
CN110214141B (zh) 作为ENaC抑制剂的苯并二唑鎓化合物
TWI908705B (zh) 化合物
TWI736566B (zh) Ｔｌｒ７/８拮抗劑及其用途
JP7333793B2 (ja) 化合物
CN113603645A (zh) 可用作激酶抑制剂的化合物
JP2019519616A (ja) 化合物
EP3697788B1 (en) Bis(pentahydroxyhexyl)amino substituted 2-{[(3-amino-pyrazin-2-yl)formamido]methyl}-1h-1,3-benzodiazol-3-ium derivatives as enac inhibitors for treating respiratory diseases
CN114269721A (zh) 用于治疗呼吸系统疾病的化合物
CN107207477A (zh) 用于治疗病毒性疾病的亚氨基糖
BR112019009864B1 (pt) Compostos de benzodiazolínio, composição farmacêutica e produto compreendendo os referidos compostos, seus processos de fabricação e uso
HK40014276A (en) Benzodiazolium compounds as enac inhibitors
HK40014276B (en) Benzodiazolium compounds as enac inhibitors
HK40067764A (en) Compounds for treating respiratory disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant